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ABSTRACT  
Tissue engineering allows the design of functionally active cells within supportive 
bio-scaffolds to promote the development of new tissues such as cartilage and bone 
for the restoration of pathologically altered tissues[1, 2]. However, all bone tissue 
engineering applications are limited by a shortage of stem cells. The adult bone 
marrow stroma contains a subset of nonhematopoietic cells referred to bone marrow 
mesenchymal stem cells (BMSCs). BMSCs are of interest because they are easily 
isolated from a small aspirate of bone marrow and readily generate single-cell-
derived colonies. These cells have the capacity to undergo extensive replication in 
an undifferentiated state ex vivo. In addition, BMSCs have the potential to develop 
either in vitro or in vivo into distinct mesenchymal tissues, including bone, cartilage, 
fat, tendon, muscle, and marrow stroma. Thus, BMSC is an attractive cell source for 
tissue engineering approaches.  However, BMSC are not homogeneous and the 
quantity of stem cells decreases in bone marrow in aged population[3-5]. A 
sequential loss of lineage differentiation potential has been found in the mixed 
culture of bone marrow stromal cells due to heterogenous population. Therefore, a 
number of studies have proposed that homogenous bone marrow stem cells can be 
generated from clonal culture of bone marrow cells and that BMSC clones have the 
greatest potential for the application of bone regeneration in vivo. 
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BACKGOUND 
Large bone defects, due to pathological and traumatic reasons, face great clinical 
challenges because of the shortage of donor bone tissue. Autologous bone graft is 
considered the best option, but has the limitation of donor sites.  At present, tissue 
engineering is a new approach for bone regeneration and endeavours to repair large 
bone losses using 3 dimensional (3-D) scaffolds to deliver vital cells to the defective 
site. However, all the bone tissue engineering applications are limited by a shortage 
of stem cells. 
Bone marrow contains a subclass of stem-like cells that are precursors of non-
hematopoietic tissues. Friedenstein originally referred to them as fibroblastic colony–
forming units (CFU-f)[6].  Stem cells are undifferentiated multipotent precursor cells 
that share two characteristic properties: unlimited or prolonged self-renewal and 
potency for differentiation. Therefore, stem cell-based therapies hold promise for 
treating degenerative disorders and injuries[7-9]. When stem cells head down the 
pathway toward differentiation, they usually proceed by first giving rise to a more 
specialized kind of stem cell called precursor cell or “progenitor cell”, which can in 
turn either proliferate through self-renewal or produce fully specialized or 
differentiated cells. 
Despite the launch of preliminary human trials and the great variety of the data 
available, a number of fundamental questions still need to be resolved. For example, 
it has been noted that a sequential loss of lineage differentiation potential occurs in 
the mixed culture of bone marrow stromal cells due to the heterogeneity of the cell 
population[10]. One notable question that arises is whether these precursor cells are 
pluripotential and homogenous, that is, true stem cells, or whether they are a mixture 
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of cells committed to various lineages of differentiation (specialized progenitors). In 
particular, it is not known if all, or only some, of these precursors are osteogenic. In 
addition, little is known about the biochemical and molecular phenotype of the 
starting cell populations. Although several cell surface markers can be used to 
recognize BMSC, no unique marker for these cells is known[11]. Thus, it is difficult to 
estimate the in vitro culture homogeneity, and to identify BMSC niches in vivo. 
Although some mesenchymal lineage-inducing agents are known, the molecular 
details regulating the lineage development still need to be investigated[12, 13].  
 
Bone marrow stromal cells – Heterogenous nature. 
Cultured BMSCs are an interesting target for use in cell and gene therapy because 
of the ease with which they proliferate readily and give rise to differentiated progeny 
that can substitute the diseased counterpart[14]. Bone marrow has been defined as 
a complex tissue comprised of hematopoietic precursors, their differentiated 
progeny, and a connective tissue network referred to as stroma[15, 16]. The marrow 
stromal tissue is a heterogeneous mixture of cells including adipocytes, reticulocytes, 
endothelial cells, and fibroblastic cells which are in direct contact with the 
hematopoietic elements. It has been recognised by many investigators that the 
adherent cell layer emerging from primary marrow cultures is composed of different 
cell populations[17]. Our current study found that primary culture of bone marrow 
stromal cells contained at least three types of cells. Based on morphologic 
appearance they are spindle shaped cells, star shaped cells and large flat cells. 
Furthermore, large numbers of genes have been found to be differently expressed 
between individual samples within the same group when cultured bone marrow cells 
were analysed by microarray study. Figure 1 shows the individual expression of 
5 
 
35,000 genes in three bone marrow cell samples collected from healthy juveniles 
while the figure 2 shows gene expression in three bone marrow cell samples from 
healthy adults. Over 150 genes showed two fold difference between samples within 
juvenile group and more than 124 genes showed two-fold different expression 
between samples within adult group.  Heterogenous cell populations of bone marrow 
samples may therefore be the major reason of the large gene variation between 
individual samples. Hence, the purification of stem cell population from the mixed 
culture of bone marrow samples is imperative to understand the nature of 
mesenchymal stem cells located in bone marrow. 
 
                  
                          Figure 1                                  Figure 2                  
   
 
 
Clone culture and in vitro expansion of BMSCs 
BMSCs are of interest because they are easily isolated from a small aspirate of bone 
marrow and readily generate single cell derived colonies. Recently, several stem-
cell-related surface marker proteins have been used for the isolation and functional 
Figure 1 and 2 show microarray results from 3 individual bone marrow 
samples of juvenile patient (figure 1) and adults (figure 2). Each line 
indicates a single gene expressed in 3 samples. 
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characterization of human mesenchymal stem cells [15, 18].  However, 
mesenchymal stem cells express mesenchymal, muscle, epithelial, and endothelial 
cell surface markers[11] and the absence of a unique antibody profile for 
mesenchymal progenitor or stem cells have hampered the purification of stem cells 
from a mixed population using cell surface marker selection.  
The single cell-derived colonies of BMSC can be expanded through as many as 50 
population doublings in about 10 weeks, and they can differentiate into osteoblasts, 
adipocytes, chondrocytes, myocyte, astrocytes, oligodendrocytes, and neurons[19] . 
Hence it is the hypothesis that single clonal culture of bone marrow cells provides a 
unique approach to characterizing the composition of a marrow stromal cell 
population. Currently in our lab we have successfully established and stored 19 
clones from three patient’s bone marrow samples (Figure 3). Single cells were 
isolated from the primary bone marrow culture and subsequently explanted. Of 192 
clonal cell cultures from each patient (total 576 clonal cultures), only 19 clones can 
be continuously cultured and stored. These clones showed a continued proliferation 
and were able to reach confluence in 75 flask in less than 8 weeks under conditioned 
culture.  These results demonstrated the possibility to establish the method of single 
cell culture for subsequent analysis and it is promising in harvesting clones of stem 
cells from bone marrow[20-22].  
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Figure 3: Clone numbers generated from the single cell culture of three BMSC 
samples                 
 
         
FGF-2 growth factor and its significance in BMSC culture 
With extended culture in the conditions currently in use, human BMSC display a 
tendency to lose their multipotentiality, proliferation potential and in vivo bone 
forming efficiency[23]. Further, their use in gene and cell therapy requires their in 
vitro expansion and calls for the investigation of culture conditions required to 
preserve these cells as a stem cell compartment with high differentiative potential 
during their life span.  
Basic fibroblast growth factor (FGF-2) acts as a pleiotropic factor mediating aspects 
of bone formation and resorption. Regulated expression and activation of basic FGF 
and its receptors are critical in normal skeletal development. In skeletal tissues, 
FGF-2 is produced by cells of the osteoblastic lineage, accumulates in bone matrix, 
and acts as an autocrine/paracrine factor. It has been reported that among many 
growth factors intrinsic to the skeletal tissues, FGF-2 or basic FGF is recognized as a 
potent mitogen for a variety of mesenchymal cells and is the most effective growth 
factor in promoting mesenchymal stem cell proliferation[24, 25]. Previous studies 
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have shown that FGF-2 is a more potent mitogen for immature mesenchymal cells, 
prechondrocytes, and preosteoblasts than for differentiated osteoblasts. The addition 
of basic FGF-2 to primary cultures of BMSC helps to maintain their osteogenic 
potential and this effect is associated with a longer telomere size in the cultured 
cells[26]. FGF-2 supplementation prolongs the life span of bone marrow stromal cells 
to more than 70 doublings and maintains their differentiation potential until 50 
doublings. It has been  suggested that FGF-2 in vitro selects for the survival of a 
particular subset of cells enriched in pluripotent mesenchymal precursors and is 
useful in obtaining a large number of cells with preserved differentiation potential for 
mesenchymal tissue repair [26]. 
In our clone cell culture medium, supplemented with FGF-2, a single clone cell can 
keep its spindle morphology and can be enriched (figure 4), whereas, in standard 
cell culture medium with 10% FCS, cell morphology started to change to a round 
shape and cell growth stopped after a few passages.  It was noted that not a single 
clone was able to reach the stage of cell confluence in a T75 flask without FGF-2.    
 
Figure 4: This figure shows single cell derived from BMSC that reached confluence 
after two weeks when cultured under standard medium supplemented with FGF-2. a) 
shows a single cell in 96-well culture plate; b) shows cell proliferation after 3 days 
and c) shows cells nearly confluent after two weeks in 96-well plate.  
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Telomere length and Telomerase activity during cell division: 
A number of studies [27-30] have focussed on the effect of the invitro expansion on 
the replicative capacity of mesenchymal stem cells by correlating their rate of 
telomere loss during in vitro expansion with their behaviour in vivo. Telomere 
shortening is the cause of replicative senescence of mammalian cells in culture and 
may be a cause of cellular aging in vivo. Telomeres are composed of the tandem 
DNA repeats and associated proteins that cap the ends of linear chromosomes. 
They provide stability to the chromosome and protect against DNA loss associated 
with cellular replication. Telomeres are maintained by the reverse transcriptase, 
telomerase. The regulation of telomere length and telomerase activity is a complex 
and dynamic process that is tightly linked to cell cycle regulation. There is a 
significant decline of telomeres length and telomerase activity in the long term 
culture of BMSCs[31, 32]. The clones generated from BMSCs require substantial 
passages to get enough cells for the telomere length and telomerase analysis, 
therefore, it is likely that no telomerase activity is detectable from clone cultures.    
Genes responsible for osteoblast differentiation 
Verfaille[33-35] assesed the genetic pathways involved in osteoblast differentiation. 
Osteogenesis is a strictly controlled developmental process in which numerous 
extrinsic factors, including hormones and growth factors, activate osteoblast-specific 
signalling proteins and transcription factors (TFs) required for osteoblast 
differentiation. TFs Cbfa1/osf2 have been shown to regulate the expression of genes 
that characterize the osteoblast phenotype, including osteocalcin (OCN), osteopontin 
(OPN), type I collagen, bone sialoprotein (BSP), and collagenase-3. Cbfa-1 deficient 
mice lack bone formation because of a maturation arrest of osteoblasts.  Molecular 
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and genetic evidence has demonstrated that Cbfa1/osf2 activates osteoblast 
differentiation during embryonic development in mice and humans. In addition, it can 
induce osteoblast differentiation of non osteoblastic cells.   
 
Clonal characterization of bone marrow stromal cells 
Our present studies [20-22]based on single cell clonal cultures have demonstrated a 
wide variation in the proliferation rates among the 14 individual clones derived from 
three patients' bone marrow samples. There is even a marked variation within clones 
from the same sample. These wide variations in cell replication are directly related 
with differentiation potential. Fast growing clones have demonstrated 
multipotentiality, whereas, slow growing clones have showed a limited differentiation 
potential and changes in cell morphology and signs of cell senescence. The 
morphology changes and decreased proliferation are signs of BMSCs to committed 
lineage. These findings indicate the importance to develop protocol for identifying 
fast growing cells from heterogeneous population in bone marrow samples for 
potential cell based therapy. Therefore, cell surface markers have been explored in 
comparing the fast and slow growing clones as well as the mixed bone marrow 
samples. However there is no difference in the expression of known phenotype 
markers currently most used for MSCs amongst fast growing clones, slow growing 
clones and mixed BMSCs. All clones expressed the putative mesenchymal markers 
CD29, CD44, CD73, CD90, CD105, CD166 and MHC class I, but did not express the 
haematopoietic markers CD34, CD45 and MHC class II (Figure 5). 
This finding indicates there is a strong need to investigate for novel cell surface 
characteristic markers of BMSCs. It will be of interest to find a unique marker which 
could identify fast growing multipotential cells early in culture.  
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 Figure 5:  FACS analysis of surface epitopes in clonal cultures and mixed culture. 
Clonally isolated BMSC cultured for 20 PDs and the mixed cultures were labeled 
with PE or FITC-conjugated Abs against human CD29, CD34, CD44, CD45, CD73, 
CD90, CD105, CD166, MHC-I and MHC-II or Ig isotope controls. Fluorescence 
intensity corresponds to the percent of cells with specific antibody staining profile 
(shaded peak towards right side of the plot), as compared to nonspecific 
fluorescence of cell population stained with the secondary antibody (IgG1 PE). The 
x-axis corresponds to the fluorescence intensity and the y–axis corresponds to the 
cell count. Histogram shows the flow cytometry results of the surface epitopes of the 
fast growing clones, slow growing clones and the mixed BMSC population. 
 
Molecular regulators in clone culture and stemness 
A number of factors have been considered to attribute to different stem cell 
properties of MSC clones such as the microenvironment MSC harboured and culture 
12 
 
conditions [36, 37]. We have confirmed that slow-growing cells expressed higher 
level of cell senescence related genes such as p53, p16, and Rb1 compared with 
fast-growing cells.  The specific molecular mechanisms must underlie the stemness 
of the clones exhibiting superior ex vivo expansion potential.   It is revealed a pool of 
ten up-regulated genes which are common in all the fast-growing clones as opposed 
to the genes expressed in slow-growing clones.   They are associated with the 
maintenance of self-renewal and lineage markers of a wide array of cell types 
(embryonic, neural and endodermal), in addition to those specific for MSCs.  They 
include genes encoding proteins involved in the maintenance of embryonic stem cell 
renewal and endodermal organogenesis such as Sox2 and Fox A2 [38], expression 
markers associated with chondrogenesis such as ACAN and COL2A1 and growth 
factors such as BMP2 and IGF1, which are involved in both cell proliferation, as well 
as induction of differentiation in a context dependent manner [39]. Other genes that 
were expressed include NOTCH1 and DLL3, which are involved in stem cell 
maintenance in diverse niches [40, 41] and cell cycle regulators, FGF2 and CDC2 
[25, 42].     
 
Immunological properties of the in vitro cultured BMSC and their in vivo bone 
forming efficiency            
Allogeneic organ or tissue transplantation involves use of powerful 
immunosuppressive drugs – carrying undesirable side effects to prevent 
immunological rejection of the transplanted tissue.  In the absence of such 
immunosuppression, the patient’s T- lymphocytes and natural killer cells (NK) 
recognize surface molecules on the transplanted cells as “foreign” and attack and 
destroy the cells. Also, in whole organ transplantation, donor T-lymphocytes and 
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natural killer cells, entering the recipient from the transplanted organ, can also 
destroy the tissues of the transplant recipient (called “graft versus host” disease).  
Interestingly, Drukker[43] showed that embryonic stem cells (ESCs) in vitro express 
very low levels of the immunologically crucial major histocompatibility complex class 
I (MHC-I) proteins on their cell surface. The presence of MHC-I proteins increases 
moderately when the ESCs become differentiated, whether in vitro or in vivo. A more 
pronounced increase in MHC-I antigen expression has been observed when the 
ESCs are exposed to gamma-interferon, a protein produced in the body during 
immune reactions. To study the feasibility of human BMSC transplantation, the in 
vitro immunogenicity of MSCs and their ability to function as alloantigen presenting 
cells need to be evaluated. Early studies showed that human MSC did not induce 
allogeneic T cells to proliferate, even when their major histocompatibility complex 
(MHC) class 2 antigen was upregulated and a co-stimulatory signal was provided by 
an anti-CD28 antibody[44]. Additionally it has been found that intravenous infusion of 
allogenic, major histocompatibility mismatched BMSC into baboons is well tolerated 
in most animals and prolonged survival of skin allografts[45, 46]. 
Investigations with regard to the immune suppressive behaviour of MSCs and their 
immunomodulatory aspects would support the possibility that transplantation of 
human MSCs might be accomplished with minimal or no host suppression. 
 
In summary, the cellular and molecular properties of BMSCs can possibly be 
generated from projects designed to (1) isolate bone marrow stem cells using clone 
culture method, (2) identify genetic difference between stem cell and specialized 
progenitors and compare their immunogenicity, (3) test the purified bone marrow 
stem cells for long-term engraftment of bone formation in vivo.  
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